Key Highlights
- Third-quarter net loss was USD 2,238,528, against USD 2,286,991.
- Research and development costs rose 32.9% to USD 1,616,962.
- A Warrant Fair Value gain of USD 773,527 lifted results.
- Cash was USD 3,258,901 at quarter end.
Without a USD 773,527 gain on the change in fair value of derivative instruments, the third-quarter loss at eXoZymes (NASDAQ:EXOZ) would have been much wider. The gain came from remeasuring a warrant liability, with no Derivatives outstanding a year earlier. The net loss was USD 2,238,528 versus USD 2,286,991, a 2.1% decrease, even as operating costs rose.
The company reported no Operating Income in either period. Total operating costs were USD 3,046,448 versus USD 2,522,208, up 20.8%, which is also the net operating loss. Research and Development costs rose 32.9% to USD 1,616,962 from USD 1,216,762 on higher salary, Bonus accruals, stock-based compensation and laboratory expenses, along with reduced grant funding. The company said the decrease in grant funding was not tied to any specific event.
General and Administrative Detail
General and administrative costs were USD 1,429,486 versus USD 1,305,446, up 9.5%. Compensation was USD 926,435, up 9.6%, reflecting new hires not funded by grants. Professional fees were USD 279,211, up 17.4%, on higher consulting and corporate legal fees. Information technology costs were USD 14,719 and other costs were USD 209,121. Net interest income was USD 21,731 versus USD 59,185, and other income was USD 12,662 versus USD 176,032.
Nine Months
Total operating costs were USD 8,387,313 versus USD 7,020,981, up 19.5%. Research and development costs rose 60.9% to USD 4,176,128, while general and administrative costs fell 4.9% to USD 4,211,185, with professional fees down 32.2% to USD 771,774. Compensation rose 14.1% to USD 2,884,827 on higher stock-based compensation.
The net loss was USD 7,487,389 versus USD 6,503,698, up 15.1%. Results included a USD 946,386 gain on derivative instruments and USD 201,784 of offering costs from the June 2026 offering. Net interest income fell 83.9% to USD 37,287.
Balance Sheet and Funding
Cash and cash equivalents were USD 3,258,901 at September 30, 2026 versus USD 3,039,343 at year end. Grants receivable fell to USD 216,923 from USD 517,359 on the completion of certain grants and timing of drawdowns. Total Assets were USD 5,862,684 versus USD 5,971,517.
Total liabilities rose 42.6% to USD 3,671,241, including a new warrant Liability of USD 1,129,085, and Accounts Payable were USD 1,330,404. Additional paid-in Capital rose to USD 30,783,515 from USD 24,501,933, and the accumulated Deficit was USD 28,592,081. Total Equity fell 35.5% to USD 2,191,443 from USD 3,397,249.
For nine months, Operating Activities used USD 5,386,342 versus USD 4,528,240, investing activities used USD 222,368 and financing provided USD 5,828,268. Working Capital was USD 2,210,334, down USD 162,353 from year end.
The company received a USD 283,805 grant from the National Institutes of Health BioClick program in March 2025 for a cell-free high-throughput platform. On July 1, 2025 it was awarded a USD 3 million share of a USD 9.2 million National Science Foundation CFIRE grant led by Georgia Tech. It closed an underwritten public offering on June 9, 2026 and a concurrent registered direct offering on June 30, 2026.
Where the Quarter Leaves eXoZymes
Spending is rising in research while grant funding recedes, and the improvement in the headline loss owes much to a non-cash warrant remeasurement. The company has one reportable segment and USD 3,258,901 of cash. The pace of research spending, grant reimbursement and swings in the warrant liability, which can move reported results from quarter to quarter, are the points to follow.






Please wait processing your request...